Pregnancy, Babies, Parenting News & Tips

Vanderbilt Scientists Discover Potential New Way to Treat Anxiety

By Staff Reporter / Aug 04, 2013 07:03 PM EDT
  • Lawrence Marnett, Ph.D., and Sachin Patel, M.D., Ph.D., Vanderbilt University Medical Center
  • (Photo : Vanderbilt University/Stephen Doster) Lawrence Marnett, Ph.D., (left) and Sachin Patel, M.D., Ph.D., have discovered that chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects.

Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report next week.

Endocannabinoids are natural signaling molecules that activate cannabinoid receptors in the brain, the same receptors turned on by the active ingredient in marijuana.

Like Us on Facebook

These receptors are also found in the gastrointestinal system and elsewhere in the body, and there is evidence that they play a role in wide range of physiological and pathological processes, in addition to modulating stress and anxiety.

If the "substrate-selective" COX-2 inhibitors developed at Vanderbilt also work in humans without side effects, they could represent a new approach to treating mood and anxiety disorders, the researchers conclude in a paper to be posted online Sunday in the journal Nature Neuroscience.

Clinical trials of some of these potential drugs could begin in the next several years, said Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology and the paper's co-senior author with Sachin Patel, M.D., Ph.D.

The Vanderbilt scientists are pursuing other potential applications of activating endocannabinoids by substrate-selective COX-2 inhibition, including relieving pain, treating movement disorders, and possibly preventing colon cancer.

"The door is really wide open," said Patel, assistant professor of Psychiatry and of Molecular Physiology & Biophysics. "We've just scratched the surface."

Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) relieve pain and inflammation by blocking either or both of the cyclooxygenase (COX) enzymes, which produce pro-inflammatory prostaglandins.

It has been known for several years that COX-2 inhibition also activates endocannabinoids.

Because the "substrate selective" inhibitors developed at Vanderbilt increase endocannabinoid levels in the mouse without blocking prostaglandin production, "we think (they) will not have the gastrointestinal and possibly cardiovascular side effects that other NSAIDs do," said Marnett, University Professor and Mary Geddes Stahlman Professor of Cancer Research.

"We thought we knew everything there was to know about (COX-2 inhibitors) until about five years ago when we discovered the substrate selective inhibition," he added. The approach used by the Vanderbilt team "is a really powerful way to help design the next generation of drugs."

Provided by Vanderbilt University Medical Center

Dutch to destroy 8,000 ducks to prevent bird flu outbreak

Dutch to destroy 8,000 ducks to prevent bird flu outbreak

Read More »

Saudi Arabia tackles MERS virus, still hunting source

Saudi Arabia tackles MERS virus, still hunting source

Read More »

Mali records new Ebola case, linked to dead nurse

Mali records new Ebola case, linked to dead nurse

Read More »

"Assassin's Creed Unity" game delay hurts GameStop's revenue

The GameStop store sign is seen at its shop in Westminster, Colorado January 14, 2014.

Read More »

New York, Missouri patients test negative for Ebola virus

1 of 2. A view of Bellevue Hospital in the Manhattan borough of New York November 20, 2014.

Read More »

U.S. entrepreneur considered suing Uber over tracking activities

An illustration picture shows the logo of car-sharing service app Uber on a smartphone next to the picture of an official German taxi sign in Frankfurt, September 15, 2014.

Read More »

U.S. states get more, spend more on Medicaid under Obamacare: report

Six-month-old Hazel Garcia chews a pamphlet at a health insurance enrollment event in Cudahy, California March 27, 2014.

Read More »

Rocket Internet to launch another 10 start-ups in 2015

The logo of of Rocket Internet, a German venture capital group is pictured in this September 24, 2014 illustration photo in Sarajevo.

Read More »

World's top drugmaker Novartis takes aim at tech

1 of 2. Joe Jimenez, CEO of Swiss drugmaker Novartis gestures during an interview with Reuters at the company's headquarters in Basel March 19, 2014. Reuters/Arnd Wiegmann

Read More »

Hagel seeks to reassure U.S. troops about safety of Ebola mission

U.S. Secretary of Defense Chuck Hagel participates in the Washington Ideas Forum, in Washington October 29, 2014.

Read More »

Pfizer dampens Astra bid hopes with German Merck cancer deal

The Pfizer logo is seen at their world headquarters in New York April 28, 2014.

Read More »

AstraZeneca trumpets standalone strength in drug development

A sign is seen at an AstraZeneca site in Macclesfield, central England April 28, 2014.

Read More »

Real Time Analytics